FirstWord Pharma: rBIO steps in as big insulin makers scale back legacy products
Why this story matters
FirstWord Pharma spotlights a looming supply gap in human‑insulin formulations as major manufacturers pivot to next‑gen analogues. The piece positions rBIO and its biosimilar candidate R‑biolin as timely, lower‑cost relief—especially after animal studies showed bioequivalence to Novolin® R.
“With Novo Nordisk and Eli Lilly prioritising GLP‑1s, smaller biotech players like rBIO could become critical to averting future shortages of essential insulins,” the article notes.
Key takeaways
Bioequivalence confirmed: Pre‑clinical data demonstrate pharmacokinetic and pharmacodynamic parity with Novolin® R.
50× scale‑up underway: rBIO reports pilot‑plant runs that multiply output fifty‑fold ahead of first‑in‑human trials.
Cost advantage: rBIO’s continuous‑fermentation platform aims for a step‑change reduction in cost of goods versus recombinant‑DNA processes.
See how rBIO is transforming insulin affordability and access.
